Welcome to Paid Research Studies




  • Condition:   Thyroid Nodule
    Intervention:   Device: Ultrasound diagnosis
    Sponsors:   Xin-Wu Cui;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Wuhan Hospital of Traditional Chinese and Western Medicine;   Macheng People's Hospital;   Huangshi Central Hospital;   Affiliated Hospital of Jiangsu University;   The First People's Hospital of Yichang;   The Second People's Hospital of Yichang;   Xiangyang Central Hospital;   the Second Affiliated Hospital of Anhui Medical University;   Anqing People's Hospital;   Huainan People's Hospital;   Taizhou Hospital;   Wenzhou Central Hospital;   Xuzhou First People's Hospital;   The Central Hospital of Lishui City;   Huai'an First People's Hospital;   WISCO General Hospital;   Jiangxia District First People's Hospital;   Enshi State Central Hospital;   Lianyungang Third People's Hospital;   Xiangyang First People's Hospital
    Recruiting

  • Condition:   Thyroid Nodule
    Intervention:   Diagnostic Test: ultrasound gray-scale ratio
    Sponsor:   First People's Hospital of Hangzhou
    Not yet recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Genetic: •Referral to Genetic Counselor, if indicated
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting

  • Condition:   Thyroid Nodule
    Intervention:  
    Sponsor:   Assiut University
    Not yet recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Benign Thyroid Nodules
    Intervention:   Procedure: Radiofrequency ablation
    Sponsor:   University Hospital, Toulouse
    Recruiting

  • Condition:   Thyroid Surgery
    Intervention:   Drug: Sugammadex 200 MG in 2 ML Injection
    Sponsors:   Seoul National University Hospital;   SMG-SNU Boramae Medical Center
    Not yet recruiting

  • Condition:   Thyroid Neoplasms
    Intervention:   Drug: Lenvatinib
    Sponsor:   Eisai Inc.
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Radiation: 99mTc sestamibi
    Sponsor:   Washington Hospital Center
    Recruiting

  • Condition:   Differentiated Thyroid Cancer
    Intervention:   Drug: rhTSH
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Condition:   Thyroid Diseases
    Intervention:   Procedure: Transoral endoscopic thyroidectomy vestibular approach
    Sponsor:   The University of Hong Kong
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Procedure: Thyroid lobectomy;   Procedure: Total thyroidectomy with CCND
    Sponsor:   University of Pittsburgh
    Recruiting

  • Conditions:   Anaplastic Thyroid Cancer;   Thyroid Cancer
    Intervention:   Drug: MLN0128
    Sponsors:   Dana-Farber Cancer Institute;   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Drug: Regorafenib
    Sponsors:   Dana-Farber Cancer Institute;   Bayer
    Recruiting

  • Condition:   Thyroid Nodule
    Intervention:   Diagnostic Test: ultrasound and FNA
    Sponsor:   Rambam Health Care Campus
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Drug: Thyrogen;   Radiation: I-131;   Radiation: I-124
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Thyroid Nodule
    Intervention:   Drug: ethanol injection
    Sponsor:   hassan harby mohamed
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Radiation: I131 1.1 GBq
    Sponsors:   University College, London;   Cancer Research UK
    Recruiting

  • Condition:   Thyroid Gland Nodule
    Intervention:   Other: Diagnostic DNA Methylation Signature
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Benign Thyroid Nodule
    Interventions:   Dietary Supplement: Preparation with Spirulina;   Dietary Supplement: Placebo
    Sponsor:   Fundatia Bio-Forum
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:  
    Sponsor:   Grupo Espanol de Tumores Neuroendocrinos
    Not yet recruiting

  • Condition:   Thyroid
    Interventions:   Drug: Metformin Hydrochloride;   Other: Radioactive Iodine;   Other: Placebo
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Differentiated Thyroid Cancer
    Interventions:   Drug: Apatinib Oral Tablet;   Drug: Placebo Oral Tablet
    Sponsor:   Peking Union Medical College Hospital
    Recruiting

  • Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Cabozantinib (XL184) 140 mg;   Drug: Cabozantinib (XL184) 60 mg;   Drug: Placebo tablet;   Drug: Placebo capsule
    Sponsor:   Exelixis
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Radiation: radioiodine
    Sponsor:   Taichung Veterans General Hospital
    Recruiting

  • Condition:   Cancer, Thyroid
    Interventions:   Diagnostic Test: Ultrasound;   Diagnostic Test: Shear wave elasticity imaging;   Diagnostic Test: Multi-angle compound shear wave elasticity imaging
    Sponsor:   Emory University
    Recruiting

  • Condition:   Thyroid Cancer, Anaplastic
    Interventions:   Drug: Nexavar;   Procedure: operation;   Radiation: External radiation therapy
    Sponsor:   Fujian Medical University
    Recruiting

  • Condition:   Thyroid Neoplasms
    Intervention:   Drug: Lenvatinib
    Sponsor:   Eisai Co., Ltd.
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Procedure: PET Imaging;   Other: 18F-tetrafluoroborate (18F-TFB)
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Drug: Durvalumab (Medi4736);   Radiation: Radioiodine (RAI)
    Sponsors:   Memorial Sloan Kettering Cancer Center;   AstraZeneca;   MedImmune LLC
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Procedure: care management pathways
    Sponsor:   University Hospital, Toulouse
    Not yet recruiting

  • Condition:   Differentiated Thyroid Cancer
    Interventions:   Drug: Cabozantinib;   Drug: Placebo
    Sponsor:   Exelixis
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Procedure: total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection;   Procedure: total thyroidectomy alone without neck dissection
    Sponsor:   Gustave Roussy, Cancer Campus, Grand Paris
    Not yet recruiting

  • Condition:   Medullary Thyroid Carcer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Papillary Thyroid Microcarcinoma
    Intervention:   Other: Active Surveillance
    Sponsor:   Cedars-Sinai Medical Center
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Drug: Lenvatinib;   Drug: Everolimus
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Condition:   Papillary Thyroid Microcarcinoma
    Interventions:   Procedure: Radiofrequency Ablation;   Procedure: Conventional Surgery
    Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University
    Recruiting

  • Conditions:   Thyroid Cancer Stage IV;   Radiation Toxicity
    Interventions:   Radiation: Intensity Modulated Radiotherapy;   Procedure: Surgery alone
    Sponsors:   Tata Memorial Hospital;   Department of Atomic Energy
    Recruiting

  • Condition:   Differentiated Thyroid Cancer
    Interventions:   Drug: Donafenib;   Drug: Placebo
    Sponsor:   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    Recruiting

  • Conditions:   Thyroid Cancer;   Graves Disease
    Intervention:   Device: Cervical Collar Therapy Indicator (COTI)
    Sponsor:   Johns Hopkins University
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Behavioral: patient interviews;   Behavioral: CITSAV survey
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Thyroid
    Intervention:  
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting

  • Condition:   Medullary Thyroid Cancer
    Intervention:   Other: 18F-DOPA
    Sponsor:   Institut Claudius Regaud
    Recruiting

  • Conditions:   Thyroid Nodule;   Thyroid Cancer
    Intervention:   Other: Thyroid Decision Aid
    Sponsor:   Mayo Clinic
    Recruiting

  • Condition:   Thyroid Cancer Metastatic
    Intervention:   Drug: Lenvatinib + Denosumab
    Sponsor:   Centre Leon Berard
    Not yet recruiting

  • Condition:   Thyroid Cancer
    Intervention:  
    Sponsor:   National Taiwan University Hospital
    Recruiting

  • Condition:   Metastatic Thyroid Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Sirolimus
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Behavioral: Questionnaires
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Acne Vulgaris;   Thyroid Dysfunction
    Intervention:  
    Sponsor:   Assiut University
    Not yet recruiting

  • Conditions:   Thyroid Carcinoma;   Metastatic Thyroid Carcinoma
    Interventions:   Device: PET/CT Scan;   Drug: Iodine-124
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Medullary Thyroid Cancer
    Intervention:   Diagnostic Test: 18F-fluorocholine PET/CT
    Sponsors:   University Medical Centre Ljubljana;   Institute of Oncology Ljubljana
    Recruiting

  • Condition:   Thyroid Cancer, Medullary
    Interventions:   Drug: 177Lu-PP-F11N;   Drug: Sacuitril
    Sponsors:   University Hospital, Basel, Switzerland;   Krebsforschung Schweiz, Bern, Switzerland;   Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland;   University Hospital, Zürich;   University Hospital Freiburg
    Recruiting

  • Condition:   Thyroid Eye Disease
    Interventions:   Drug: Hyaluronic Acid Gel injection;   Drug: Saline injection
    Sponsor:   University of California, Los Angeles
    Recruiting

  • Condition:   Malignancy of Thyroid Nodules
    Intervention:   Drug: MIBI-Tc99m/Iodine-123
    Sponsor:   Nantes University Hospital
    Recruiting

  • Condition:   Non-Medullary Thyroid Cancer
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Medullary Thyroid Cancer
    Intervention:   Drug: Ponatinib
    Sponsors:   Antonio Fojo;   Millennium Pharmaceuticals, Inc.
    Not yet recruiting

  • Conditions:   Benign Thyroid Nodule;   Quality of Life
    Intervention:   Procedure: Thyroidectomy
    Sponsor:   Aristotle University Of Thessaloniki
    Recruiting

  • Condition:   Thyroid Cancer, Medullary
    Intervention:   Drug: 177Lu-PP-F11N
    Sponsors:   University Hospital, Basel, Switzerland;   Krebsforschung Schweiz, Bern, Switzerland;   Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland;   University Hospital, Zürich;   University Hospital Freiburg
    Recruiting

  • Condition:   Thyroid Eye Disease
    Interventions:   Drug: Celecoxib;   Drug: artificial tears
    Sponsor:   Johns Hopkins University
    Recruiting

  • Condition:   Anaplastic Thyroid Cancer
    Interventions:   Drug: Trametinib;   Drug: Paclitaxel
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Novartis
    Recruiting

  • Condition:   Papillary Thyroid Cancer
    Intervention:   Drug: Imatinib Oral Tablet
    Sponsors:   AHS Cancer Control Alberta;   Alberta Cancer Foundation
    Recruiting

  • Condition:   Anaplastic Thyroid Cancer
    Intervention:   Drug: Pembrolizumab
    Sponsors:   University of Texas Southwestern Medical Center;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Thyroid Eye Disease
    Interventions:   Drug: ASTED;   Dietary Supplement: Selenium;   Other: Placebo
    Sponsor:   Iran University of Medical Sciences
    Not yet recruiting

  • Condition:   Thyroid Cancer Stage I
    Intervention:  
    Sponsors:   University Health Network, Toronto;   Ontario Ministry of Health and Long Term Care;   Canadian Cancer Society Research Institute (CCSRI)
    Recruiting

  • Condition:   Anaplastic Thyroid Cancer
    Intervention:   Other: Tissue, blood and clinical data collection
    Sponsor:   Velindre NHS Trust
    Recruiting

  • Condition:   Follicular Thyroid Cancer
    Intervention:   Other: sophrology sessions
    Sponsor:   Assistance Publique Hopitaux De Marseille
    Not yet recruiting

  • Condition:   Thyroid Disorder
    Intervention:   Other: self completed questionnaire
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting

  • Condition:   Refractory Hurthle Cell Thyroid Cancer
    Interventions:   Drug: sorafenib;   Drug: everolimus
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Novartis
    Recruiting

  • Condition:   Thyroid Cancer, Papillary
    Intervention:   Procedure: prophylactic central lymph node dissection
    Sponsor:   Seoul National University Hospital
    Recruiting

  • Condition:   Thyroid Eye Disease
    Intervention:  
    Sponsor:   University of Pittsburgh
    Recruiting

  • Condition:   Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
    Interventions:   Drug: Trametinib;   Drug: Dabrafenib;   Radiation: 131I;   Drug: rhTSH
    Sponsor:   Gustave Roussy, Cancer Campus, Grand Paris
    Recruiting

  • Conditions:   Metastatic Anaplastic Thyroid Cancer;   Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer
    Intervention:   Drug: Ceritinib
    Sponsors:   University of Texas Southwestern Medical Center;   Novartis
    Recruiting

  • Condition:   Thyroid Eye Disease
    Interventions:   Drug: Methylprednisolone + ASTED;   Drug: Methylprednisolone +Placebo
    Sponsor:   Iran University of Medical Sciences
    Not yet recruiting

  • Condition:   Medullary Thyroid Cancer (MTC)
    Intervention:   Drug: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Thyroid Nodule;   Thyroid Cancer;   Quality of Life
    Intervention:  
    Sponsor:   Oslo University Hospital
    Recruiting

  • Conditions:   Thyroid Cancer;   Endoscopy
    Interventions:   Procedure: high position space group;   Procedure: low position space group
    Sponsor:   Fujian Medical University
    Recruiting

  • Conditions:   Differentiated Thyroid Cancer;   Osteoporosis
    Interventions:   Drug: 99Tc-MDP;   Drug: fosamax;   Drug: Caltrate
    Sponsor:   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    Recruiting

  • Condition:   Thyroid Carcinoma
    Intervention:   Drug: Surufatinib
    Sponsor:   Hutchison Medipharma Limited
    Recruiting

  • Conditions:   Thyroid Nodule;   Diagnoses Disease
    Interventions:   Diagnostic Test: circulating tumor cells test;   Diagnostic Test: Fine needle aspiration biopsy
    Sponsors:   Cancer Institute and Hospital, Chinese Academy of Medical Sciences;   China-Japan Friendship Hospital;   Chinese PLA General Hospital;   Beijing Chao Yang Hospital
    Recruiting

  • Condition:   Medullary Thyroid Carcinoma
    Intervention:   Other: PET at 18F-FDOPA
    Sponsor:   Assistance Publique Hopitaux De Marseille
    Not yet recruiting

  • Conditions:   Laryngeal Nerve;   Thyroid Surgery
    Intervention:   Procedure: Monitoring
    Sponsor:   The Royal Wolverhampton Hospitals NHS Trust
    Recruiting

  • Conditions:   Thyroid Cancer;   Recurrent Laryngeal Nerve Injuries
    Intervention:   Procedure: Reversed Tracking Method
    Sponsor:   Fujian Medical University
    Recruiting

  • Conditions:   Thyroid;   HIV Infections
    Intervention:   Other: Assay of TSH, FT3 and FT4 by immuno-radiometric method
    Sponsor:   Centre Hospitalier Universitaire, Amiens
    Recruiting

  • Conditions:   Thyroid Gland; Node;   Lactation
    Interventions:   Dietary Supplement: iodine;   Dietary Supplement: Placebo
    Sponsors:   Göteborg University;   Sahlgrenska University Hospital, Sweden
    Recruiting

  • Condition:   Differentiated Thyroid Cancer
    Interventions:   Other: NLSCP;   Other: ICT supported HAP
    Sponsor:   National Taiwan University Hospital
    Not yet recruiting

  • Conditions:   Stage I Papillary Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Papillary Thyroid Cancer
    Interventions:   Procedure: Thyroidectomy;   Procedure: Central lymph node dissection;   Other: Quality-of-life assessment
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI);   National Institutes of Health (NIH)
    Recruiting

  • Conditions:   Lymph Node Dissection;   Lymph Node Metastases;   Differentiated Thyroid Carcinoma
    Intervention:   Procedure: contralateral central lymph node dissection
    Sponsor:   Fifth Affiliated Hospital, Sun Yat-Sen University
    Recruiting

  • Conditions:   Papillary Thyroid Cancer;   Lymph Node Metastases
    Interventions:   Drug: IV adminstration of EMI-137;   Device: Multispectral Fluorescence Reflectance Imaging;   Device: Spectroscopy
    Sponsors:   University Medical Center Groningen;   UMC Utrecht
    Recruiting

  • Conditions:   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Anaplastic Thyroid Carcinoma;   Poorly Differentiated Thyroid Cancer
    Interventions:   Drug: Nab-paclitaxel - INDUCTION COHORT;   Drug: Paclitaxel - INDUCTION COHORT;   Drug: Vemurafenib - COHORT 1;   Drug: Cobimetinib - COHORT 1;   Drug: Atezolizumab - COHORT 1;   Drug: Bevacizumab - COHORT 3;   Drug: Nab-paclitaxel - COHORT 4;   Drug: Paclitaxel - COHORT 4;   Drug: Cobimetinib - COHORT 2;   Drug: Atezolizumab - COHORT 2;   Drug: Atezolizumab - COHORT 3;   Drug: Atezolizumab - COHORT 4
    Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Other: Decision aid and SDM booster;   Other: Deliberation training
    Sponsors:   Radboud University;   Dutch Cancer Society
    Not yet recruiting

  • Conditions:   Papillary Thyroid Cancer;   Lymph Node Metastases
    Intervention:   Diagnostic Test: OSNA test
    Sponsor:   University of Cagliari
    Recruiting

  • Conditions:   Symptomatic, Aggressive, Sporadic, Unresectable, Locally;   Advanced/Metastatic Medullary Thyroid Cancer (MTC)
    Intervention:   Drug: Vandetanib 300 mg
    Sponsors:   Genzyme, a Sanofi Company;   Worldwide Clinical Trials
    Recruiting

  • Conditions:   Thyroid Cancer;   Papillary Thyroid Microcarcinoma
    Intervention:  
    Sponsor:   Seoul National University Hospital
    Recruiting

  • Conditions:   Thyroid-associated Ophthalmopathy;   Dry Eye Syndrome
    Interventions:   Drug: Methylprednisolone;   Drug: Esomeprazole
    Sponsor:   Medical University of Vienna
    Recruiting

  • Conditions:   Positron-Emission Tomography;   Lymph Node Metastases;   Thyroid Cancer
    Interventions:   Diagnostic Test: 18F-FDG PET/CT dynamic scan;   Diagnostic Test: B-ultrasonography
    Sponsor:   Fifth Affiliated Hospital, Sun Yat-Sen University
    Recruiting

  • Conditions:   Metastatic Thyroid Papillary Carcinoma;   Metastatic Thyroid Follicular Carcinoma;   Metastatic Thyroid Cancer
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab
    Sponsors:   Grupo Espanol de Tumores Neuroendocrinos;   MFAR
    Recruiting

  • Conditions:   Differentiated Thyroid Gland Carcinoma;   Thyroid Gland Follicular Carcinoma;   Thyroid Gland Papillary Carcinoma
    Intervention:   Drug: Lenvatinib
    Sponsors:   Emory University;   Eisai Inc.
    Recruiting

  • Conditions:   Thyroid;   Neuromuscular Blockade;   Anesthesia Complication;   Anesthesia Intubation Complication
    Interventions:   Drug: Rocuronium 0.3 mg*kg;   Drug: No Rocuronium
    Sponsor:   Federico Longhini
    Recruiting

  • Conditions:   Thyroid Cancer;   Hypoparathyroidism;   Marker; Structural;   Complication of Surgical Procedure;   Parathyroid Function Low Adverse Event
    Intervention:   Procedure: The suture marks the location of the parathyroid gland
    Sponsor:   Bo Wang,MD
    Recruiting

  • Conditions:   Hurthle Cell Thyroid Cancer;   Tall Cell Variant Thyroid Cancer;   Follicular Thyroid Cancer;   Thyroid Cancer;   Papillary Thyroid Cancer
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Thyroid Associated Ophthalmopathy
    Interventions:   Genetic: DNA extraction and genetic characterization;   Device: Orbit MRI examination;   Other: Collection of life style data
    Sponsor:   Sun Yat-sen University
    Recruiting

  • Conditions:   Burns;   Liver Fibroses;   Pancreas Disease;   Thyroid Diseases
    Intervention:   Device: Ultrasound/transient elastography
    Sponsor:   The University of Texas Medical Branch, Galveston
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Diagnostic Test: Cerenkov luminescence imaging.
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Behavioral: Prayer;   Behavioral: non-prayer
    Sponsor:   Yonsei University
    Recruiting

  • Conditions:   Thyroid; Deficiency;   Quality of Life
    Intervention:   Drug: Levothyroxine Sodium
    Sponsor:   Klinikum Lüdenscheid
    Not yet recruiting

  • Condition:   Thyroid Tumor
    Interventions:   Drug: Desflurane;   Drug: Remifentanil;   Procedure: Thyroidectomy;   Other: Vital signs;   Behavioral: Cough reflex;   Behavioral: Ramsay Sedation Scale;   Other: Extubation time and Recovery time;   Behavioral: Visual analogue scale;   Other: Postoperative bleeding;   Other: Postoperative complications;   Other: Time to remove drainage and duration of hospital staying;   Drug: Dexmedetomidine;   Drug: Normal saline
    Sponsor:   Chosun University Hospital
    Recruiting

  • Conditions:   Thyroid Cancer;   Postsurgical Hypothyroidism
    Intervention:   Drug: Levothyroxine
    Sponsors:   University of Texas Southwestern Medical Center;   Akrimax Pharmaceuticals
    Recruiting

  • Conditions:   Hyperthyroidism;   Hypothyroidism
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Thyroid Cancer;   Thyroid Cancer, Medullary;   Differentiated Thyroid Cancer;   Papillary Thyroid Cancer;   Follicular Thyroid Cancer;   Poorly Differentiated Thyroid Gland Carcinoma
    Interventions:   Drug: Lenvatinib;   Drug: Sorafenib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  • Condition:   Thyroid Diseases
    Intervention:   Drug: Prophylactic protocol with Ca and Vit D
    Sponsor:   Hellenic Red Cross Hospital
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting

  • Conditions:   RET-altered Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   RET-altered Papillary Thyroid Cancer;   RET-altered Colon Cancer;   RET-altered Solid Tumors
    Intervention:   Drug: BLU-667
    Sponsor:   Blueprint Medicines Corporation
    Recruiting

  • Condition:   Lymph Node Metastases
    Intervention:   Procedure: lymph node dissection
    Sponsor:   Zhejiang University
    Not yet recruiting

  • Conditions:   Central Hypothyroidism;   Hypothyroidism;   Hyperthyroidism
    Interventions:   Diagnostic Test: Indirect calorimetry;   Diagnostic Test: Dual energy X-ray Absorptiometry (DXA);   Diagnostic Test: Blood sampling
    Sponsors:   University Hospital, Basel, Switzerland;   University of Zurich
    Recruiting

  • Condition:   Lymph Node Metastases
    Intervention:   Procedure: lymph node dissection
    Sponsor:   Zhejiang University
    Not yet recruiting

  • Conditions:   Thyroidectomy;   Thyroid Cancer;   Central Compartment Neck Dissction
    Interventions:   Procedure: Conventional;   Procedure: central neck dissection first
    Sponsor:   Fujian Medical University
    Recruiting

  • Condition:   Thyroid Neoplasms
    Interventions:   Drug: Deep Group;   Drug: Control Group
    Sponsor:   Yonsei University
    Not yet recruiting

  • Conditions:   Thyroid Cancer;   Thyroid Nodule
    Intervention:   Other: No intervention: observational only
    Sponsor:   University of Virginia
    Not yet recruiting

  • Conditions:   Iodine Excess in Pregnancy;   Selenium Excess in Pregnancy;   Iodine Deficiency in Pregnancy;   Selenium Deficiency in Pregnancy
    Intervention:   Other: Not applicable (for observational studies)
    Sponsor:   Rongrong Li
    Not yet recruiting

  • Conditions:   Cancer Survivor;   Caregiver;   Family Member;   Health Care Provider;   Thyroid Gland Medullary Carcinoma
    Interventions:   Other: Decision Aid;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
    Interventions:   Radiation: Iodine I-131;   Other: Placebo;   Drug: Selumetinib
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BRAF Gene Mutation;   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   RAS Family Gene Mutation;   Recurrent Thyroid Gland Carcinoma;   Refractory Thyroid Gland Carcinoma;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
    Interventions:   Procedure: Computed Tomography;   Radiation: Iodine I 124;   Radiation: Iodine I-131;   Other: Laboratory Biomarker Analysis;   Other: Pharmacodynamic Study;   Procedure: Positron Emission Tomography;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Differentiated Thyroid Gland Carcinoma;   Follicular Variant Thyroid Gland Papillary Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Progressive Disease;   Refractory Thyroid Gland Carcinoma;   Tall Cell Variant Thyroid Gland Papillary Carcinoma;   Thyroid Gland Follicular Carcinoma;   Thyroid Gland Hurthle Cell Carcinoma;   Thyroid Gland Papillary Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Hypothyroidism
    Intervention:   Drug: Isovue
    Sponsor:   Bracco Diagnostics, Inc
    Recruiting

  • Conditions:   Thyroid Disease;   Parathyroid Diseases
    Interventions:   Drug: Non-narcotic group regimen;   Drug: Narcotic group regimen
    Sponsor:   MetroHealth Medical Center
    Recruiting

  • Conditions:   Hypocalcemia;   Thyroid Diseases
    Interventions:   Dietary Supplement: Tums;   Dietary Supplement: Calcitriol
    Sponsor:   Lahey Clinic
    Recruiting

  • Conditions:   Dyslipidemia;   Subclinical hypothyroïdism;   Statin;   ASCVD
    Interventions:   Drug: Pitavastatin and placebo;   Drug: Pitavastatin and levothyroxine
    Sponsors:   Shaochun.Li;   Chinese Academy of Medical Sciences, Fuwai Hospital;   Peking University Third Hospital;   Beijing Chao Yang Hospital;   Xuanwu Hospital, Beijing;   Beijing Friendship Hospital
    Recruiting

  • Conditions:   Thyroid Cancer;   Thyroid Nodule;   Thyroid Adenoma
    Interventions:   Procedure: Flexible fiberoptic laryngoscopy;   Procedure: Direct laryngoscopy
    Sponsor:   Istanbul University
    Recruiting

  • Conditions:   Thyroid Cancer;   Papillary Thyroid Carcinoma;   Thyroidectomy;   Endoscopy
    Interventions:   Device: used of the Pressure adjustable foot-control method;   Device: direct exhaust
    Sponsor:   Bo Wang,MD
    Recruiting

  • Condition:   Postpartum Thyroiditis
    Intervention:  
    Sponsor:   China National Nuclear Corporation 416 Hospital
    Recruiting

  • Conditions:   Vocal Cord Paralysis;   Recurrent Laryngeal Nerve
    Intervention:   Drug: Group B. Sugammadex sodium-IONM
    Sponsor:   Lütfiye Nuri Burat Government Hospital
    Recruiting

  • Conditions:   Myocardial Infarction;   Hypothyroidism
    Intervention:   Drug: Levothyroxine
    Sponsors:   Chinese Academy of Medical Sciences, Fuwai Hospital;   Beijing Municipal Science & Technology Commission;   Peking Union Medical College Hospital;   Peking University Third Hospital;   Beijing Anzhen Hospital;   Beijing Chao Yang Hospital;   Beijing Friendship Hospital;   The Luhe Teaching Hospital of the Capital Medical University
    Recruiting

  • Condition:   Thyroid Associated Ophthalmopathy
    Interventions:   Radiation: Orbital radiotherapy;   Drug: Methylprednisolone
    Sponsor:   University of Pisa
    Not yet recruiting

  • Conditions:   Thyroid Cancer;   Squamous Head and Neck Cancer;   HRAS Mutant Tumor
    Intervention:   Drug: Tipifarnib
    Sponsor:   Kura Oncology, Inc.
    Recruiting

  • Conditions:   Endoscopy;   Robotics;   Thyroidectomy;   Papillary Thyroid Carcinoma
    Interventions:   Procedure: conventional open surgery;   Procedure: endoscopic thyroidectomy;   Device: robotic thyroidectomy
    Sponsor:   Fujian Medical University
    Recruiting

  • Condition:   Ophthalmopathy, Thyroid-Associated
    Interventions:   Drug: Rituximab;   Drug: Iv Methylprednisolone;   Drug: peroral methylprednisolone and Methotrexate
    Sponsors:   Göteborg University;   Sahlgrenska University Hospital, Sweden
    Recruiting

  • Condition:   Healthy
    Intervention:   Other: Dosages of Thyroid parameters
    Sponsor:   University Hospital, Caen
    Not yet recruiting

  • Condition:   Postoperative Pain
    Interventions:   Drug: local anesthetic;   Drug: Dexmedetomidine
    Sponsor:   Assiut University
    Recruiting

  • Condition:   Selenium Deficiency
    Intervention:   Diagnostic Test: detection of serum selenium
    Sponsor:   Peking Union Medical College Hospital
    Recruiting

  • Condition:   Selenium Deficiency
    Interventions:   Dietary Supplement: selenium supplementation;   Dietary Supplement: ordinary corn powder
    Sponsor:   Peking Union Medical College Hospital
    Not yet recruiting

  • Condition:   Metabolic Syndrome
    Intervention:  
    Sponsor:   Assiut University
    Not yet recruiting

  • Condition:   Carcinoma, Papillary, Follicular
    Intervention:   Device: Using Neuromonitoring to find EBSLN
    Sponsor:   Seoul National University Hospital
    Recruiting

  • Condition:   Sutures
    Interventions:   Device: Spiral PDS Plus;   Device: Spiral MONOCRYL Plus;   Device: PDS Plus;   Device: MONOCRYL Plus;   Device: VICRYL Plus
    Sponsor:   Ethicon, Inc.
    Not yet recruiting

  • Condition:   Bilateral Superficial Cervical Block
    Interventions:   Drug: bupivacaine;   Drug: Dexamethasone;   Device: ultrasound
    Sponsor:   Assiut University
    Recruiting

  • Conditions:   Thyroid;   Thyroid Dysfunction;   Hypothyroidism;   Pregnancy Early
    Intervention:   Diagnostic Test: Serum thyroid functions tests
    Sponsor:   Bartin State Hospital
    Recruiting

  • Conditions:   Thyroid Cancer;   Thyroid Nodule;   Thyroid Neoplasms;   Thyroid Goitre;   Thyroid Diseases;   Parathyroid Diseases;   Parathyroid Adenoma;   Parathyroid Hyperplasia
    Interventions:   Drug: Acetaminophen 500Mg Cap;   Drug: Tylenol #3 Oral Tablet;   Drug: Tramadol
    Sponsor:   Minerva Romero Arenas, MD, MPH
    Recruiting

  • Conditions:   Thyroid Cancer;   Neck Cancer;   Recurrent Laryngeal Nerve Injuries;   Accessory Nerve Injuries;   EMG: Repetitive Nerve Stimulation Abnormality
    Intervention:   Drug: Lidocaine
    Sponsor:   Bo Wang,MD
    Recruiting

  • Conditions:   Thyroid;   Parathyroid; Deficiency
    Intervention:   Drug: Indocyanine Green
    Sponsor:   Aristotle University Of Thessaloniki
    Recruiting

  • Condition:   Subclinical Hypothyroidism
    Interventions:   Drug: Levothyroxine;   Drug: Liothyronine;   Drug: Thyrotropin-Releasing Hormone
    Sponsors:   University of Pennsylvania;   National Institute on Aging (NIA)
    Recruiting

  • Conditions:   Thyroid Associated Ophthalmopathy;   Hypercholesterolemia
    Interventions:   Drug: Atorvastatin;   Drug: Methylprednisolone
    Sponsor:   University of Pisa
    Not yet recruiting

  • Conditions:   Columnar Cell Variant Thyroid Gland Papillary Carcinoma;   Follicular Variant Thyroid Gland Papillary Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage III Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage III Thyroid Gland Follicular Carcinoma AJCC v7;   Stage III Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7;   Tall Cell Variant Thyroid Gland Papillary Carcinoma;   Thyroid Gland Oncocytic Follicular Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lenvatinib;   Biological: Pembrolizumab
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Breast Cancer;   Thyroid Dysfunction
    Intervention:   Drug: Triiodothyronine (T3)
    Sponsor:   Aultman Health Foundation
    Recruiting

  • Conditions:   Myelofibrosis;   Acute Lymphocytic Leukemia (ALL);   Lymphoblastic Lymphoma;   Thyroid Cancer
    Intervention:   Drug: Navitoclax
    Sponsor:   AbbVie
    Available

  • Conditions:   Breast Cancer;   Stomach Neoplasms;   Salivary Gland Neoplasms;   Thyroid Cancer
    Intervention:  
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Medullary Thyroid Cancer;   Infantile Myofibromatosis;   Infantile Fibrosarcoma;   Papillary Thyroid Cancer;   Soft Tissue Sarcoma
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting

  • Condition:   Advanced Nonhaematologic Malignancies
    Intervention:   Drug: BOS172738
    Sponsor:   Boston Pharmaceuticals
    Recruiting

  • Conditions:   Thyroid Gland; Node;   Pregnancy;   Cognitive Developmental Delay
    Interventions:   Dietary Supplement: Iodine;   Dietary Supplement: Placebo
    Sponsors:   Göteborg University;   Sahlgrenska University Hospital, Sweden
    Recruiting

  • Conditions:   Platinum Resistant Ovarian Cancer;   Non Small Cell Lung Cancer Metastatic;   Papillary Renal Cell Carcinoma;   Papillary Thyroid Cancer;   Salivary Gland Cancer
    Intervention:   Drug: XMT-1536
    Sponsors:   Mersana Therapeutics;   Novella Clinical
    Recruiting

  • Conditions:   Endocrine Tumors;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands
    Interventions:   Drug: Selumetinib;   Drug: Olaparib
    Sponsors:   M.D. Anderson Cancer Center;   AstraZeneca
    Recruiting

  • Conditions:   Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer;   Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer;   Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
    Intervention:   Other: data collection
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Conditions:   Adhesion;   Thyroidectomy
    Intervention:   Combination Product: MEDICLORE
    Sponsors:   Seoul National University Hospital;   Daewoong Pharmaceutical Co. LTD.
    Recruiting

  • Condition:   Allan-Herndon-Dudley Syndrome
    Intervention:   Drug: Triac
    Sponsor:   Erasmus Medical Center
    Not yet recruiting

  • Conditions:   Ovarian Cancer;   Cervical Cancer;   Endometrial Cancer;   Non Small Cell Lung Cancer;   Thyroid Cancer;   Melanoma;   Sarcoma
    Intervention:   Biological: HuMax-AXL-ADC
    Sponsor:   Genmab
    Recruiting

  • Conditions:   Thyroid Diseases;   Heart Diseases;   Bone Diseases;   Brain Diseases;   Kidney Diseases
    Intervention:   Diagnostic Test: SPECT-CT Scan
    Sponsor:   Lille Catholic University
    Recruiting

  • Conditions:   Hypothyroidism;   Biomarkers;   Endocrine System Diseases
    Interventions:   Drug: Levothyroxin;   Drug: Liothyronine
    Sponsors:   Oslo University Hospital;   Hormonlaboratoriet;   Spesialistsenteret Pilestredet Park
    Recruiting

  • Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breastcancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting

  • Condition:   Microbiota
    Intervention:   Drug: Probiotic
    Sponsor:   First Affiliated Hospital of Harbin Medical University
    Recruiting

  • Conditions:   Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
    Intervention:   Drug: Entrectinib
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Breast Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Other Solid Tumors With Evidence of Activating RET Alteration
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Available

  • Condition:   Hypothyroidism
    Interventions:   Drug: Iohexol;   Drug: Iodixanol;   Drug: Iopromide
    Sponsors:   GE Healthcare;   Bayer;   Duke Clinical Research Institute
    Not yet recruiting

  • Conditions:   Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
    Intervention:   Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
    Sponsor:   British Columbia Cancer Agency
    Available

  • Conditions:   Carcinoma, Non-Small-Cell Lung;   Thyroid Neoplasms;   Sarcoma;   Colorectal Neoplasms;   Salivary Gland Neoplasms;   Biliary Tract Neoplasms;   Brain Neoplasm, Primary;   Melanoma;   Glioblastoma;   Bile Duct Neoplasms;   Astrocytoma;   Head and Neck Squamous Cell Carcinoma;   Pontine Glioma;   Pancreatic Neoplasms;   Ovarian Neoplasms;   Carcinoma, Renal Cell;   Cholangiocarcinoma;   Skin Carcinoma;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms, Nerve Tissue;   Nevi and Melanomas;   Intestinal Neoplasms;   Thyroid Cancer;   GIST;   Malignant Peripheral Nerve Sheath Tumors;   Breast Secretory Carcinoma;   Uterine Neoplasms;   Fibrosarcoma;   Infantile Fibrosarcoma;   Congenital Mesoblastic Nephroma;   Central Nervous System Neoplasms
    Intervention:   Drug: LOXO-195
    Sponsors:   Loxo Oncology, Inc.;   Bayer
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
    Intervention:   Drug: IACS-010759
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Neoplasm;   Castleman Disease;   Digestive System Carcinoma;   Erdheim-Chester Disease;   Lip and Oral Cavity Carcinoma;   Lymphangioleiomyomatosis;   Malignant Endocrine Neoplasm;   Malignant Female Reproductive System Neoplasm;   Malignant Male Reproductive System Neoplasm;   Malignant Neoplasm;   Malignant Respiratory Tract Neoplasm;   Malignant Thoracic Neoplasm;   Malignant Urinary System Neoplasm;   Mesothelial Neoplasm;   Metastatic Malignant Neoplasm;   Metastatic Urothelial Carcinoma;   Neurofibromatosis Type 2;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Breast Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Digestive System Carcinoma;   Recurrent Female Reproductive System Carcinoma;   Recurrent Male Reproductive System Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Pharyngeal Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Malignant Neoplasm;   Soft Tissue Neoplasm;   Stage III Breast Cancer AJCC v7;   Stage III Pharyngeal Cancer;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Pharyngeal Cancer;   Stage IVA Pharyngeal Cancer;   Stage IVB Pharyngeal Cancer;   Stage IVC Pharyngeal Cancer;   Thyroid Gland Neoplasm
    Interventions:   Biological: Bevacizumab;   Biological: Cetuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Temsirolimus;   Drug: Valproic Acid
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pheochromocytoma;   Paraganglioma;   Inherited Cancer Syndrome;   Associated Conditions;   Kidney Neoplasms;   Bone Cancer;   Thyroid Neoplasms;   Other Cancer
    Intervention:   Genetic: Genetic screening
    Sponsor:   The University of Texas Health Science Center at San Antonio
    Recruiting

  • Conditions:   Aging;   Primary Hypothyroidism;   Interaction Drug Food
    Interventions:   Other: Evening Levothyroxine Administration;   Other: Morning Levothyroxine Administration
    Sponsors:   Hospital de Clinicas de Porto Alegre;   Federal University of Rio Grande do Sul
    Recruiting

  • Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   MITF Positive;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hyperthyroidism
    Intervention:   Drug: Propranolol
    Sponsor:   University Hospital, Basel, Switzerland
    Recruiting

  • Condition:   Hypothyroidism
    Intervention:   Drug: Calcitonin
    Sponsor:   University of Maryland
    Recruiting

  • Condition:   Hypothyroidism;Postablative
    Intervention:   Drug: levothyroxine sodium capsule
    Sponsor:   IBSA Institut Biochimique SA
    Recruiting

  • Condition:   Hypothyroidism
    Interventions:   Drug: Liothyronine;   Drug: Levothyroxin;   Drug: Placebos
    Sponsor:   Azienda USL Modena
    Recruiting

  • Condition:   Hypothyroidism
    Intervention:   Drug: Levothyroxine
    Sponsors:   Jocelyne Karam;   Maimonides Medical Center
    Recruiting

  • Conditions:   Sarcoma;   Ovarian Neoplasm;   Central Nervous System Neoplasm;   Thyroid Neoplasm;   Carcinoma, Neuroendocrine;   Neoplasms, Germ Cell and Embryonal;   NK/T-cell Lymphoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   UNICANCER;   National Cancer Institute, France;   Ligue contre le cancer, France;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Hyperthyroid
    Intervention:   Behavioral: Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
    Sponsor:   University Hospital, Angers
    Recruiting

  • Conditions:   Mesothelioma;   Bladder Cancer;   Melanoma;   Squamous Cell Carcinoma of the Head and Neck;   Non Small Cell Lung Cancer;   Clear Cell Renal Cell Carcinoma;   Ovarian Cancer;   Thyroid Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer;   Colon Cancer;   Soft Tissue Sarcoma
    Intervention:   Biological: MGD009
    Sponsor:   MacroGenics
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Neoplasms of Uncertain or Unknown Behavior
    Interventions:   Drug: Neratinib;   Drug: Everolimus;   Drug: Palbociclib;   Drug: Trametinib
    Sponsors:   M.D. Anderson Cancer Center;   Puma Biotechnology, Inc.
    Recruiting

  • Conditions:   Liver Cancer Stage IV;   Gastric Cancer Stage IV;   Esophageal Cancer, Stage IV;   Bone and Soft Tissue Tumors;   Breast Cancer Stage IV;   Bladder Carcinoma Stage IV;   Prostate Carcinoma Stage IV;   Thyroid Cancer Stage IV;   Ovarian Cancer Stage IV;   Solid Tumor
    Intervention:   Drug: TAEST16001
    Sponsors:   Zhujiang Hospital;   Xiangxue Life Science Research Center;   Guangdong Xiangxue Precision Medical Technology Co., Ltd.;   Xiangxue Pharmaceutical
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Renal Cell Carcinoma;   Non-Small Cell Lung Cancer;   Castration-resistant Prostate Cancer;   Triple Negative Breast Cancer;   Ovarian Cancer;   Endometrial Cancer;   Hepatocellular Carcinoma;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   Colorectal Cancer;   Head and Neck Cancer;   Differentiated Thyroid Cancer
    Interventions:   Drug: cabozantinib;   Drug: atezolizumab
    Sponsor:   Exelixis
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
    Interventions:   Drug: TAK-228;   Drug: Paclitaxel;   Drug: Carboplatin
    Sponsors:   M.D. Anderson Cancer Center;   Takeda
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Melanoma and Other Malignant Neoplasms of Skin
    Interventions:   Drug: Cyclophosphamide;   Drug: Etoposide;   Procedure: NK Cell Infusion;   Drug: Mesna
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract
    Interventions:   Drug: Pembrolizumab;   Biological: Clostridium Novyi-NT;   Drug: Doxycycline
    Sponsors:   M.D. Anderson Cancer Center;   BioMed Valley Discoveries, Inc;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Neoplasms of Uncertain or Unknown Behavior
    Interventions:   Drug: Avelumab;   Drug: Utomilumab;   Drug: PF-04518600;   Radiation: Radiation;   Drug: Cisplatin
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting

  • Conditions:   Malignant Neoplasm of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasm of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Melanoma and Other Malignant Neoplasms of Skin
    Intervention:   Drug: Gemcitabine
    Sponsors:   M.D. Anderson Cancer Center;   James B. and Lois R. Archer Charitable Foundation;   Gateway for Cancer Research
    Recruiting

  • Conditions:   Hematological Malignancies;   Chronic Hypoxemic Respiratory Failure;   Blood And Marrow Transplantation;   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
    Interventions:   Other: Non-Invasive Positive Pressure Ventilation (NIPPV);   Other: High Flow Nasal Cannula Oxygen Therapy
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Gestational Diabetes Mellitus in Pregnancy;   Gestational Hypertension;   Thyroid Disease Pregnancy;   Obesity;   Anemia in Pregnancy;   Complications, Pregnancy;   Depression;   Obstetric Labor Complications;   Asthma;   Allergic Disorder;   Immune System Diseases;   Neurodevelopmental Disorders;   Reproductive Disorder
    Intervention:   Other: No intervention
    Sponsors:   Sun Yat-sen University;   Huizhou First Maternal and Child Care Service Center
    Recruiting

  • Condition:   Amiodarone-Induced Thyrotoxicosis
    Intervention:   Device: RFA
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   Hyperthyroidism;   Thyroidectomy;   PTH;   Immunochromatographic
    Intervention:  
    Sponsor:   Bo Wang,MD
    Recruiting

  • Conditions:   Cancer, All Types;   Cancer of Liver;   Cancer of Stomach;   Cancer of Head and Neck;   Cancer of Rectum;   Cancer of Kidney;   Cancer of Esophagus;   Cancer of Colon;   Cancer Skin;   Cancer of Cervix;   Cancer, Metastatic;   Cancer of Larynx;   Cancer of Neck;   Cancer of Lung;   Cancer of Brain and Nervous System;   Cancer of Vulva, Disseminated;   Cancer of Pancreas;   Sarcoma;   GIST;   Small-cell Lung Cancer;   Adenocarcinoma Lung;   Cancer of Prostate;   Cancer, Advanced;   Adrenal Cancer;   Testicular Cancer;   Uterine Cancer;   Bronchoalveolar Cell Lung Cancer;   Cancer Unknown Primary;   Glioblastoma Multiforme;   Oligodendroglioma;   Breast Cancer;   Renal Cell Carcinoma;   Hepatocellular Carcinoma;   Cholangiocarcinoma;   Squamous Cell Carcinoma;   Transitional Cell Carcinoma;   Cancer, Other;   Cancer, Anal;   Melanoma;   Cancer, Bile Duct;   Cancer, Bladder;   Cancer Cords Vocal;   Cancers Cell Neuroendocrine;   Cancer Differentiated Poorly;   Cancer, Anaplastic Thyroid
    Intervention:  
    Sponsors:   SpeciCare;   Dana-Farber Cancer Institute;   Kalispell Regional Medical Center;   Georgia Institute of Technology;   Ontario Institute for Cancer Research;   SEngine Precision Medicine;   Helomics
    Recruiting

  • Conditions:   Kidney Medullary Carcinoma;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Doxorubicin;   Drug: Gemcitabine;   Drug: Ixazomib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Renal Medullary Carcinoma;   Other Disorders of Kidney and Ureter
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Autoimmune Thyroiditis
    Interventions:   Dietary Supplement: SelenoPRECISE;   Dietary Supplement: Placebo
    Sponsors:   Steen Bonnema;   Rigshospitalet, Denmark;   Bispebjerg Hospital;   Hospital of South West Denmark;   Pharma Nord;   The Danish Medical Research Council;   Region of Southern Denmark;   University of Southern Denmark
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Cell Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Plasmacytoid Urothelial Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Sarcomatoid Urothelial Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Total Thyroidectomy;   Near-total Thyroidectomy
    Interventions:   Drug: Period 1 GX-30, Period 2 THYROGEN®;   Drug: Period 1 THYROGEN®, Period 2 GX-30
    Sponsors:   Genexine, Inc.;   Symyoo
    Recruiting

  • Conditions:   Infertility;   Autoimmune Thyroiditis
    Interventions:   Drug: Immunomodulatory;   Drug: Thyroxine
    Sponsor:   Aljazeera Hospital
    Recruiting

  • Conditions:   Pleuropulmonary Blastoma;   Cystic Nephroma;   Ovarian Sertoli-Leydig Cell Tumors;   Ocular Medulloepithelioma;   Nasal Chondromesenchymal Hamartoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Intraoperative Parathyroid Scores System
    Intervention:   Behavioral: with IPSS
    Sponsor:   Fujian Medical University
    Recruiting

  • Conditions:   Surgery--Complications;   Acute Illness;   Gastrointestinal Disease;   Stress
    Intervention:   Procedure: Major emergency gastrointestinal surgery
    Sponsor:   Zealand University Hospital
    Recruiting

  • Condition:   Graves Disease
    Intervention:   Device: Echopulse
    Sponsor:   The University of Hong Kong
    Recruiting

  • Condition:   Graves' Disease
    Intervention:   Drug: K1-70 intramuscular
    Sponsor:   AV7 Limited
    Recruiting

  • Condition:   Autoimmune Encephalitis
    Intervention:   Other: oculomotor movement recordings, neurovisual assessment
    Sponsor:   Hospices Civils de Lyon
    Not yet recruiting

  • Condition:   Autoimmune Encephalitis
    Interventions:   Drug: Ocrelizumab;   Drug: Saline
    Sponsors:   University of Texas Southwestern Medical Center;   Genentech, Inc.
    Recruiting

  • Condition:   Autoimmune Encephalitis
    Interventions:   Procedure: Plasma exchange;   Drug: IVIG, High-dose glucocorticoid
    Sponsor:   Yan Zhang
    Recruiting

  • Condition:   Graves' Ophthalmopathy
    Intervention:   Drug: RVT-1401 (Administered via subcutaneous injection)
    Sponsor:   Immunovant Sciences GmbH
    Recruiting

  • Condition:   Graves Ophthalmopathy
    Intervention:   Drug: Bimatoprost Ophthalmic
    Sponsor:   University of Washington
    Recruiting

  • Condition:   Graves Ophthalmopathy
    Intervention:   Procedure: Orbital decompression
    Sponsor:   University of Sao Paulo General Hospital
    Recruiting

  • Condition:   Graves Ophthalmopathy
    Intervention:   Drug: Methylprednisolone
    Sponsors:   Torben Harsløf;   Odense University Hospital
    Recruiting

  • Conditions:   Auto-immune Encephalitis;   Epilepsy
    Intervention:   Biological: vena punction
    Sponsors:   Erasmus Medical Center;   Nationaal Epilepsie Fonds
    Recruiting

  • Condition:   Mild Graves' Ophthalmopathy
    Interventions:   Drug: Metformin;   Drug: Placebo
    Sponsor:   Yonsei University
    Recruiting

  • Condition:   Dysthyroid Ophthalmopathies
    Intervention:  
    Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild
    Recruiting

  • Condition:   Advanced Cancer
    Intervention:   Biological: pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Chronic Heart Failure
    Intervention:  
    Sponsor:   Federico II University
    Recruiting

  • Condition:   Solid Tumors Habouring NTRK Fusion
    Intervention:   Drug: BAY2757556 (Larotrectinib, Vitrakvi)
    Sponsor:   Bayer
    Recruiting

  • Conditions:   Syncope;   Bradycardia;   Tachycardia;   Sudden Cardiac Death;   Ventricular Tachycardia;   Ventricular Fibrillation
    Intervention:   Device: implantation of cardiac devices
    Sponsor:   Klinik für Kardiologie, Pneumologie und Angiologie
    Recruiting

  • Condition:   Carotid Artery, External
    Intervention:   Device: Magnetic Resonance Imaging (MRI),
    Sponsor:   Centre Hospitalier Universitaire, Amiens
    Recruiting

  • Conditions:   Solid Tumors;   CNS Tumors;   Neuroblastoma
    Intervention:   Drug: Entrectinib
    Sponsor:   Hoffmann-La Roche
    Recruiting